NASDAQ:TNYA Tenaya Therapeutics (TNYA) Stock Price, News & Analysis $0.34 -0.01 (-2.45%) As of 10:20 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Tenaya Therapeutics Stock (NASDAQ:TNYA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tenaya Therapeutics alerts:Sign Up Key Stats Today's Range$0.34▼$0.3550-Day Range$0.32▼$0.7052-Week Range$0.30▼$1.46Volume333,160 shsAverage Volume3.43 million shsMarket Capitalization$77.27 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingModerate Buy Company Overview Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for heart disease. Based in South San Francisco, California, the company uses genetic medicine and other therapeutic approaches to target the underlying causes of cardiac conditions. Its investigational programs include TN-201, a gene therapy candidate for MYBPC3-associated hypertrophic cardiomyopathy, and TN-401, a gene therapy candidate for PKP2-associated arrhythmogenic right ventricular cardiomyopathy. Tenaya has also developed TN-301, an oral small-molecule candidate studied for heart failure with preserved ejection fraction. Tenaya’s candidates are investigational and are not approved medicines. The company was founded in 2016 and focuses its research and development on therapies for serious heart diseases.AI Generated. May Contain Errors. Read More Tenaya Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreTNYA MarketRank™: 2.870988867055 of 5 starsTenaya Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 494th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingModerate Buy Consensus RatingTenaya Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialTenaya Therapeutics has a consensus price target of $4.00, representing about 1,051.1% upside from its current price of $0.35.Amount of Analyst CoverageTenaya Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Tenaya Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Tenaya Therapeutics are expected to grow in the coming year, from ($0.36) to ($0.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tenaya Therapeutics is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tenaya Therapeutics is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTenaya Therapeutics has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.55% of the float of Tenaya Therapeutics has been sold short.Short Interest Ratio / Days to CoverTenaya Therapeutics has a short interest ratio ("days to cover") of 8.71.Change versus previous monthShort interest in Tenaya Therapeutics has recently increased by 3.95%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTenaya Therapeutics does not currently pay a dividend.Dividend GrowthTenaya Therapeutics does not have a long track record of dividend growth. News and Social Media4.3 / 5News Sentiment0.92 News SentimentTenaya Therapeutics has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Tenaya Therapeutics this week, compared to 2 articles on an average week.Search Interest6 people have searched for TNYA on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat Follows7 people have added Tenaya Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Tenaya Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,056.00 in company stock.Percentage Held by Insiders2.69% of the stock of Tenaya Therapeutics is held by insiders.Percentage Held by Institutions90.54% of the stock of Tenaya Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tenaya Therapeutics' insider trading history. Receive TNYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tenaya Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TNYA Stock News HeadlinesFY2026 Earnings Forecast for TNYA Issued By HC WainwrightNovember 9, 2026 | americanbankingnews.comH.C. Wainwright Sticks to Their Buy Rating for Tenaya Therapeutics (TNYA)November 7, 2026 | theglobeandmail.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 13 at 1:00 AM | Weiss Ratings (Ad)Tenaya Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 5, 2026 | marketscreener.comMTenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateNovember 4, 2026 | globenewswire.comTenaya Therapeutics (TNYA) Gets a Buy from Piper SandlerOctober 31, 2026 | theglobeandmail.comTenaya Therapeutics Announces RMAT Designation To TN-401September 14, 2026 | rttnews.comTenaya's TN-401 Receives FDA RMAT Status For PKP2-Associated Cardiomyopathy; Stock UpSeptember 14, 2026 | rttnews.comSee More Headlines TNYA Stock Analysis - Frequently Asked Questions How have TNYA shares performed this year? Tenaya Therapeutics' stock was trading at $0.7115 at the beginning of the year. Since then, TNYA stock has decreased by 51.2% and is now trading at $0.3475. How were Tenaya Therapeutics' earnings last quarter? Tenaya Therapeutics, Inc. (NASDAQ:TNYA) issued its earnings results on Wednesday, November, 4th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.02. The company had revenue of $1.70 million for the quarter, compared to analyst estimates of $800 thousand. When did Tenaya Therapeutics IPO? Tenaya Therapeutics (TNYA) raised $180 million in an initial public offering (IPO) on Thursday, July 29th 2021. The company issued 12,000,000 shares at $14.00-$16.00 per share. Who are Tenaya Therapeutics' major shareholders? Top institutional shareholders of Tenaya Therapeutics include Mirador Capital Partners LP (0.43%), State Street Corp (0.33%) and R Squared Ltd (0.03%). Insiders that own company stock include Faraz Ali, Timothy Hoey, Whittemore Tingley, Tomohiro Higa, Chihiro Saito and Group Gp Lp Column III. View institutional ownership trends. How do I buy shares of Tenaya Therapeutics? Shares of TNYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tenaya Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tenaya Therapeutics investors own include NVIDIA (NVDA), Immunic (IMUX), Solid Biosciences (SLDB), Viking Therapeutics (VKTX), Palantir Technologies (PLTR), Plug Power (PLUG) and Iovance Biotherapeutics (IOVA). Company Calendar Last Earnings11/04/2026Today11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 TNYA's financial health is in the Red zone, according to TradeSmith. TNYA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TNYA CIK1858848 Webwww.tenayatherapeutics.com Phone650-825-6990FaxN/AEmployees70Year Founded2016Price Target and Rating Average Price Target for Tenaya Therapeutics$4.00 High Price Target$8.00 Low Price Target$2.00 Potential Upside/Downside+1,042.9%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$90.60 million Net MarginsN/A Pretax Margin-3,356.79% Return on Equity-88.96% Return on Assets-69.51% Debt Debt-to-Equity RatioN/A Current Ratio3.78 Quick Ratio3.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.24 per share Price / Book1.46Miscellaneous Outstanding Shares227,930,000Free Float221,797,000Market Cap$79.78 million OptionableOptionable Beta2.88 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:TNYA) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredTrump compared today's market to 1929President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...USA Capital Gold | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
